Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : sciclone pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: flatsville who wrote (434)	3/1/2000 12:17:00 PM
From: AurumRabosa	Read Replies (1) \| Respond to of 1137

It's a mouthful but it's great news: According to the article, whose lead author is Cartesio Favalli, Professor of Experimental Medicine and Biochemical Sciences at the University of Rome, "MHC class-1 downregulation has been shown in many tumors and is considered an important factor in limiting immunotherapy of cancer. Thymosin alpha 1, by inducing MHC class-1 expression, could make tumor cells 'visible' to T lymphocytes and therefore less prone to escape from immune surveillance." biz.yahoo.com